{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T22:14:24Z","timestamp":1788128064124,"version":"build-2803163510"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T00:00:00Z","timestamp":1544054400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1007\/s00280-018-3739-9","type":"journal-article","created":{"date-parts":[[2018,12,6]],"date-time":"2018-12-06T14:33:48Z","timestamp":1544106828000},"page":"419-424","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Randomized phase II trial of the prophylactic use of celecoxib for the prevention of oxaliplatin-related peripheral vascular pain in Capeox (YCOG1205)"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3738-9393","authenticated-orcid":false,"given":"Yusuke","family":"Suwa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuyoshi","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Suwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuteru","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koutaro","family":"Nagamine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masashi","family":"Momiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ishibe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuke","family":"Saigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takeharu","family":"Yamanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Itaru","family":"Endo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,6]]},"reference":[{"issue":"23","key":"3739_CR1","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1056\/NEJMoa032709","volume":"350","author":"T Andr\u00e9","year":"2004","unstructured":"Andr\u00e9 T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J (2004) Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 350(23):2343\u20132351","journal-title":"N Engl J Med"},{"issue":"16","key":"3739_CR2","doi-asserted-by":"publisher","first-page":"2198","DOI":"10.1200\/JCO.2006.08.2974","volume":"25","author":"JP Kuebler","year":"2007","unstructured":"Kuebler JP, Wieand HS, O\u2019Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN (2007) Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 25(16):2198\u20132204","journal-title":"J Clin Oncol"},{"issue":"19","key":"3739_CR3","doi-asserted-by":"publisher","first-page":"3109","DOI":"10.1200\/JCO.2008.20.6771","volume":"27","author":"T Andr\u00e9","year":"2009","unstructured":"Andr\u00e9 T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F (2009) Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 27(19):3109\u20133116","journal-title":"J Clin Oncol"},{"issue":"28","key":"3739_CR4","doi-asserted-by":"publisher","first-page":"3768","DOI":"10.1200\/JCO.2011.36.4539","volume":"29","author":"G Yothers","year":"2011","unstructured":"Yothers G, O\u2019Connell MJ, Allegra CJ, Kuebler JP, Colangelo LH, Petrelli NJ, Wolmark N (2011) Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 29(28):3768","journal-title":"J Clin Oncol"},{"issue":"11","key":"3739_CR5","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1200\/JCO.2010.33.6297","volume":"29","author":"DG Haller","year":"2011","unstructured":"Haller DG, Tabernero J, Maroun J, de Braud F, Price T, Van Cutsem E, Hill M, Gilberg F, Rittweger K, Schmoll H-J (2011) Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol 29(11):1465\u20131471","journal-title":"J Clin Oncol"},{"issue":"2","key":"3739_CR6","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1007\/s10147-014-0703-5","volume":"20","author":"Y Yoshida","year":"2015","unstructured":"Yoshida Y, Hoshino S, Aisu N, Naito M, Tanimura S, Mogi A, Tanaka T, Hirata K, Tamura K, Yamashita Y (2015) Administration of chemotherapy via the median cubital vein without implantable central venous access ports: port-free chemotherapy for metastatic colorectal cancer patients. Int J Clin Oncol 20(2):332\u2013337. \n                    https:\/\/doi.org\/10.1007\/s10147-014-0703-5","journal-title":"Int J Clin Oncol"},{"issue":"3","key":"3739_CR7","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1111\/apt.12174","volume":"37","author":"C Sakamoto","year":"2013","unstructured":"Sakamoto C, Kawai T, Nakamura S, Sugioka T, Tabira J (2013) Comparison of gastroduodenal ulcer incidence in healthy Japanese subjects taking celecoxib or loxoprofen evaluated by endoscopy: a placebo-controlled, double-blind 2-week study. Aliment Pharmacol Ther 37(3):346\u2013354. \n                    https:\/\/doi.org\/10.1111\/apt.12174","journal-title":"Aliment Pharmacol Ther"},{"issue":"9","key":"3739_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1056\/NEJMoa061355","volume":"355","author":"MM Bertagnolli","year":"2006","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Solomon SD, Kim K, Tang J, Rosenstein RB, Wittes J, Corle D, Hess TM, Woloj GM, Boisserie F, Anderson WF, Viner JL, Bagheri D, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Gordon GB, Hawk ET (2006) Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 355(9):873\u2013884. \n                    https:\/\/doi.org\/10.1056\/NEJMoa061355","journal-title":"N Engl J Med"},{"issue":"4","key":"3739_CR9","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1158\/1940-6207.CAPR-08-0206","volume":"2","author":"MM Bertagnolli","year":"2009","unstructured":"Bertagnolli MM, Eagle CJ, Zauber AG, Redston M, Breazna A, Kim K, Tang J, Rosenstein RB, Umar A, Bagheri D, Collins NT, Burn J, Chung DC, Dewar T, Foley TR, Hoffman N, Macrae F, Pruitt RE, Saltzman JR, Salzberg B, Sylwestrowicz T, Hawk ET (2009) Five-year efficacy and safety analysis of the adenoma prevention with celecoxib trial. Cancer Prev Res (Phila) 2(4):310\u2013321. \n                    https:\/\/doi.org\/10.1158\/1940-6207.capr-08-0206","journal-title":"Cancer Prev Res (Phila)"},{"issue":"9","key":"3739_CR10","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1056\/NEJMoa061652","volume":"355","author":"N Arber","year":"2006","unstructured":"Arber N, Eagle CJ, Spicak J, Racz I, Dite P, Hajer J, Zavoral M, Lechuga MJ, Gerletti P, Tang J, Rosenstein RB, Macdonald K, Bhadra P, Fowler R, Wittes J, Zauber AG, Solomon SD, Levin B (2006) Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 355(9):885\u2013895. \n                    https:\/\/doi.org\/10.1056\/NEJMoa061652","journal-title":"N Engl J Med"},{"issue":"2","key":"3739_CR11","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1615\/JEnvironPatholToxicolOncol.v21.i2.90","volume":"21","author":"BS Reddy","year":"2002","unstructured":"Reddy BS, Rao CV (2002) Novel approaches for colon cancer prevention by cyclooxygenase-2 inhibitors. J Environ Pathol Toxicol Oncol 21(2):155\u2013164","journal-title":"J Environ Pathol Toxicol Oncol"},{"issue":"2","key":"3739_CR12","first-page":"68","volume":"62","author":"S Atari-Hajipirloo","year":"2016","unstructured":"Atari-Hajipirloo S, Nikanfar S, Heydari A, Noori F, Kheradmand F (2016) The effect of celecoxib and its combination with imatinib on human HT-29 colorectal cancer cells: Involvement of COX-2, Caspase-3, VEGF and NF-kappaB genes expression. Cell Mol Biol (Noisy-le-grand) 62(2):68\u201374","journal-title":"Cell Mol Biol (Noisy-le-grand)"},{"issue":"9","key":"3739_CR13","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1016\/j.bcp.2006.12.033","volume":"73","author":"N Sakoguchi-Okada","year":"2007","unstructured":"Sakoguchi-Okada N, Takahashi-Yanaga F, Fukada K, Shiraishi F, Taba Y, Miwa Y, Morimoto S, Iida M, Sasaguri T (2007) Celecoxib inhibits the expression of survivin via the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73(9):1318\u20131329. \n                    https:\/\/doi.org\/10.1016\/j.bcp.2006.12.033","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"3739_CR14","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1111\/cas.13106","volume":"108","author":"I Egashira","year":"2017","unstructured":"Egashira I, Takahashi-Yanaga F, Nishida R, Arioka M, Igawa K, Tomooka K, Nakatsu Y, Tsuzuki T, Nakabeppu Y, Kitazono T, Sasaguri T (2017) Celecoxib and 2,5-dimethylcelecoxib inhibit intestinal cancer growth by suppressing the Wnt\/beta-catenin signaling pathway. Cancer Sci 108(1):108\u2013115. \n                    https:\/\/doi.org\/10.1111\/cas.13106","journal-title":"Cancer Sci"},{"issue":"4","key":"3739_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/0304-3959(75)90075-5","volume":"1","author":"EE Ohnhaus","year":"1975","unstructured":"Ohnhaus EE, Adler R (1975) Methodological problems in the measurement of pain: a comparison between the verbal rating scale and the visual analogue scale. Pain 1(4):379\u2013384","journal-title":"Pain"},{"issue":"1","key":"3739_CR16","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/jnci\/95.1.19","volume":"95","author":"G Chvetzoff","year":"2003","unstructured":"Chvetzoff G, Tannock IF (2003) Placebo effects in oncology. J Natl Cancer Inst 95(1):19\u201329","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"3739_CR17","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1007\/s00520-014-2242-z","volume":"22","author":"AJ Beijers","year":"2014","unstructured":"Beijers AJ, Mols F, Vreugdenhil G (2014) A systematic review on chronic oxaliplatin-induced peripheral neuropathy and the relation with oxaliplatin administration. Support Care Cancer 22(7):1999\u20132007. \n                    https:\/\/doi.org\/10.1007\/s00520-014-2242-z","journal-title":"Support Care Cancer"},{"issue":"3","key":"3739_CR18","first-page":"411","volume":"38","author":"K Matsuyama","year":"2011","unstructured":"Matsuyama K, Mishima H, Ueno H, Kajihara K, Morioka A, Morimoto S, Yamauchi K, Honda Y, Komori K, Tsujinaka T (2011) Etiology and management of venous pain during intravenous administration of oxaliplatin. Jpn J Cancer Chemother 38(3):411\u2013414","journal-title":"Jpn J Cancer Chemother"},{"issue":"10","key":"3739_CR19","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1007\/s00520-009-0740-1","volume":"18","author":"R Cathomas","year":"2010","unstructured":"Cathomas R, Koberle D, Ruhstaller T, Mayer G, Rass A, Mey U, von Moos R (2010) Heated (37 degrees C) oxaliplatin infusion in combination with capecitabine for metastatic colorectal carcinoma: can it reduce neuropathy? Support Care Cancer 18(10):1263\u20131270. \n                    https:\/\/doi.org\/10.1007\/s00520-009-0740-1","journal-title":"Support Care Cancer"},{"issue":"4","key":"3739_CR20","first-page":"537","volume":"40","author":"R Miyajima","year":"2013","unstructured":"Miyajima R, Kawazoe H, Tsuneoka K, Fujiwara M, Kojima Y, Yakushijin Y (2013) Preventive trial of preheating administration of oxaliplatin-diluted solution in combination with a hot compress for oxaliplatin-induced venous pain. Gan To Kagaku Ryoho 40(4):537\u2013540","journal-title":"Gan To Kagaku Ryoho"},{"issue":"5","key":"3739_CR21","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1188\/13.CJON.554-555","volume":"17","author":"Y Okada","year":"2013","unstructured":"Okada Y, Sayoko Kajiume RNC, Takoko Taniguchi RNC, BCOPS SK, BCOPS YO (2013) Coadministration of 5% glucose solution and dexamethasone and oxaliplatin-related vascular pain grade: a case study. Clin J Oncol Nurs 17(5):554","journal-title":"Clin J Oncol Nurs"},{"issue":"2","key":"3739_CR22","doi-asserted-by":"publisher","first-page":"132","DOI":"10.9734\/BJMMR\/2012\/918","volume":"2","author":"Y Yoshida","year":"2012","unstructured":"Yoshida Y, Hoshino S, Aisu N, Shiwaku H, Beppu R, Tanimura S, Yamashita Y (2012) Dexamethasone as a means not only for controlling vascular pain caused by the administration of oxaliplatin via the peripheral vein but also for controlling oxaliplatin-induced hypersensitivity reactions. Br J Med Med Res 2(2):132\u2013141","journal-title":"Br J Med Med Res"},{"issue":"10","key":"3739_CR23","first-page":"1583","volume":"39","author":"Y Shiotsuka","year":"2012","unstructured":"Shiotsuka Y, Uebuchi M, Hamada S, Morita N, Moriyama A, Yamashita M, Ichikawa Y, Fujii H, Matsuo A, Kuhara H, Ikuta Y, Ikeshima S, Kuramoto M, Fujii K, Shimada S (2012) Reduction of angialgia during peripheral administration of oxaliplatin mixed with dexamethasone. Gan To Kagaku Ryoho 39(10):1583\u20131586","journal-title":"Gan To Kagaku Ryoho"},{"issue":"6","key":"3739_CR24","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/S0899-9007(98)00037-9","volume":"14","author":"T Kuwahara","year":"1998","unstructured":"Kuwahara T, Asanami S, Kubo S (1998) Experimental infusion phlebitis: tolerance osmolality of peripheral venous endothelial cells. Nutrition 14(6):496\u2013501. \n                    https:\/\/doi.org\/10.1016\/S0899-9007(98)00037-9","journal-title":"Nutrition"},{"issue":"2","key":"3739_CR25","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jclinane.2009.03.011","volume":"22","author":"B Ghai","year":"2010","unstructured":"Ghai B, Makkar JK, Bala I, Wig J (2010) Effect of parecoxib pretreatment and venous occlusion on propofol injection pain: a prospective, randomized, double-blinded, placebo-controlled study. J Clin Anesth 22(2):88\u201392. \n                    https:\/\/doi.org\/10.1016\/j.jclinane.2009.03.011","journal-title":"J Clin Anesth"},{"issue":"7","key":"3739_CR26","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.jiac.2017.02.006","volume":"23","author":"S Nagao","year":"2017","unstructured":"Nagao S, Furihata M, Fukagawa K, Furihata T, Matsuhashi Y, Wada T (2017) Premedication with fast-acting oxycodone hydrochloride hydrate effectively reduced oxaliplatin-induced severe vascular pain. J Infect Chemother 23(7):493\u2013497. \n                    https:\/\/doi.org\/10.1016\/j.jiac.2017.02.006","journal-title":"J Infect Chemother"},{"issue":"11","key":"3739_CR27","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1056\/NEJMoa050405","volume":"352","author":"SD Solomon","year":"2005","unstructured":"Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, Anderson WF, Zauber A, Hawk E, Bertagnolli M (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352(11):1071\u20131080. \n                    https:\/\/doi.org\/10.1056\/NEJMoa050405","journal-title":"N Engl J Med"},{"issue":"16","key":"3739_CR28","doi-asserted-by":"publisher","first-page":"2104","DOI":"10.1161\/CIRCULATIONAHA.108.764530","volume":"117","author":"SD Solomon","year":"2008","unstructured":"Solomon SD, Wittes J, Finn PV, Fowler R, Viner J, Bertagnolli MM, Arber N, Levin B, Meinert CL, Martin B, Pater JL, Goss PE, Lance P, Obara S, Chew EY, Kim J, Arndt G, Hawk E (2008) Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 117(16):2104\u20132113. \n                    https:\/\/doi.org\/10.1161\/circulationaha.108.764530","journal-title":"Circulation"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-018-3739-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-018-3739-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,5]],"date-time":"2019-12-05T19:09:36Z","timestamp":1575572976000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-018-3739-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,6]]},"references-count":28,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["3739"],"URL":"https:\/\/doi.org\/10.1007\/s00280-018-3739-9","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,6]]},"assertion":[{"value":"22 October 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 November 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 December 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}